Auto Accident
  Slip and Fall
  Medical Malpractice
  Construction Accidents
  Wrongful Death
  Workers Compensation
  Defective Drugs
  Product Liability
  Nursing Home Negligence
  Toxic Substances
  Lead Paint Poisoning

Avandia Lawsuits Costing Glaxo Up To $6 Billion
March 9, 2010

Avandia lawsuits could end up costing GlaxoSmithKline as much as $6 billion, according to a UBS analyst.

In a note made public last Friday, the brokerage said Glaxo's Avandia lawsuit liability was in the range of $1 billion to $6 billion. "We expect liability below the midpoint of this range and note GlaxoSmithKline has underperformed by around $2.5bn already," the note said.

Glaxo faces more than 13,000 U.S. lawsuits over Avandia. These lawsuits allege that GlaxoSmithKline failed to adequately warn users about the increased risk of serious and potentially life-threatening injuries, such as heart attack, stroke, congestive heart failure, liver failure, bone fractures, macular edema (vision loss) and death.

Federal Avandia lawsuits have been consolidated for pretrial proceedings in an MDL, or multidistrict litigation, in the U.S. District Court for the Eastern District of Pennsylvania. The first bellwether, or test trials, in that litigation are expected to begin in June.

Avandia has been the subject of safety concerns for several years. In November 2007, a black box warning the Food & Drug Administration (FDA's) strongest safety warning - detailing Avandia's association with myocardial ischemia was added to the drug's labeling. The black box was added after the Cleveland Clinic published a meta- analysis of 42 clinical trails that showed patients taking Avandia had a 43-percent higher risk of having a heart attack.

Last month, the Senate Finance Committee released a report detailing its 2-year Avandia investigation. According to the report, in July 2007 the FDA's own scientists estimated that Avandia was responsible for more than 80,000 heart attacks. The Senate report also claimed that Glaxo tried to undermine criticism of the drug. The report drew on 250,000 pages of documents, including emails from GlaxoSmithKline officials, as well as interviews with Glaxo and FDA officials and anonymous whistleblowers.

Since the release of the Senate report, calls have increased for the FDA to pull Avandia off the market. The FDA is conducting another safety review of Avandia, the results of which will be discussed at a public meeting in July.


Bragoli & Associates, P.C.
300 Broadhollow Road, Suite 100 W
Melville, NY 11747
Tel. (631) 423-7755
Fax: (631) 423-5299
Toll Free: 1-888-529-9001
First Name:
Last Name:
Home Phone#:
Cell Phone#:
Bus. Phone#:
Best time to contact you:
Home Address:
Zip Code:
Please describe your case:
Date of Incident/Accident:
Other Information:
Address. 300 Broadhollow Road, Suite 100 W, Melville, NY 11747 - Tel. (631) 423-7755 - Fax. (631) 423-5299
© Copyright 2008 Bragoli & Associates,P.C.